Comments
Natco Pharma has successfully completed closure of inspection and received Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its drug formulations manufacturing facility at Visakhapatnam.
The inspection by the US drug regulator was conducted during the period from January 30 to February 3, 2023, the Hyderabad-based company said in a release.
Natco Pharma’s scrip lost 1.57 per cent on the Bombay Stock Exchange on Friday to end at ₹629.55.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.